logo
K92 Mining Releases 2024 Sustainability Report: Delivering Sustainable Value

K92 Mining Releases 2024 Sustainability Report: Delivering Sustainable Value

Yahoo05-06-2025
VANCOUVER, British Columbia, June 05, 2025 (GLOBE NEWSWIRE) -- K92 Mining Inc. ('K92' or the 'Company') (TSX: KNT; OTCQX: KNTNF) is pleased to announce that it has published its 2024 Sustainability Report. This is K92's sixth annual sustainability report, which provides details of the Company's Environmental, Social, and Governance ('ESG') practices and performance.
The 2024 Sustainability Report was prepared in accordance with the Sustainability Accounting Standards Board ('SASB') Metals and Mining Standard for the sixth consecutive year and includes continued progression of providing climate disclosures in alignment with the Task Force on Climate-related Financial Disclosures ('TCFD') recommendations.
The 2024 Sustainability Report is available on the K92 website at the following link:https://k92mining.com/responsible - mining/
Environmental, Social and Governance Highlights:
553 days without a lost-time injury(1), and a Total Recordable Injury Frequency Rate ('TRIFR') of 0.69.
1,790 employees and contractors employed in Papua New Guinea.
~92% of total workforce (employees plus contractors) are PNG Nationals with priority hiring from local communities.
$96.5 million in procurement from PNG companies, representing 42% of K92's total procurement spend.
$62.6 million in taxes and royalties paid in PNG(2), a 134% increase over 2023.
$28.0 million invested in local Joint Ventures.
$6.6 million allocated for the Company's first PNG Infrastructure Tax Credit Scheme project.
Outstanding Community Humanitarian Initiative awarded by the PNG Chamber of Resources and Energy ('CORE') for K92's Sustainable Agriculture Livelihoods Program ('SLAP'), marking the third consecutive year K92 has received the primary, annual community award from the CORE.
Launched the K92 CARES framework, which outlines the Company's core values, including a clear commitment to responsible mining practices and a culture of respect for others.
Advanced work related to the Kainantu Endowment, which was established to provide scholarships for the advancement of Papua New Guinean students.
Ongoing alignment with the TCFD recommendations with progress advanced on local hydropower improvements in support of the Company's energy and greenhouse gas ('GHG') emissions reduction target.
Continued commitment to local skills development, including a total of 66 tertiary scholarships awarded; 400+ graduates from the K92 Adult Literacy Program; and multiple Memoranda of Understanding implemented with PNG universities to help develop a robust pipeline of skilled mine workers in the country.
Supplier Code of Conduct and Employment Standard rolled out as part of ongoing due diligence work related to Canadian Modern Slavery legislation.
John Lewins, K92 Chief Executive Officer and Director, stated, 'On behalf of the K92 team, we are very pleased to publish our 2024 Sustainability Report. The report provides our primary sustainability disclosures for 2024, while highlighting many of our key initiatives that enable us to deliver sustainable value for all of our stakeholders.
The past year has been truly transformational for K92, as we advance our plans to become a world-class, Tier 1 gold mining operation. We achieved notable operational successes during the year in parallel with significant progress on our Stage 3 and Stage 4 Expansions. Importantly, we have done so with exemplary safety performance, including achieving 553 consecutive days without a lost-time injury, a testament to the robust health and safety management systems and practices we continue to implement.
Our local value-retention initiatives continue to deliver significant value for our local stakeholders. At the end of 2024, we employed nearly 1,800 employees and contractors and remained a significant tax contributor within the country, with some $62.6M in taxes and royalties paid in PNG. We also procured approximately $96.5M from PNG companies, including $28.0M from unique, local Joint Ventures, which are partnerships between established businesses and local landowner associations that help deliver significant value for local communities.
Looking ahead, the upcoming year will surely be one of the most important in K92's young history. During the year, we look forward to the commissioning of our new 1.2 million-tonnes-per-annum process plant, associated paste plant, and other key mine infrastructure to support our expansion plans and continued production growth. We also look forward to working in ongoing partnership with all our stakeholders to deliver transformational value from our operations – now and into the future.'
Notes:
(1) As at December 31, 2024. As at March 31, 2025, the number of lost-time injury free days was 643.(2) Includes corporate tax, payroll tax, import duties, and royalties. (3) All amounts are in U.S. Dollars unless otherwise noted.
About K92
K92 Mining Inc. is engaged in the production of gold, copper and silver at the Kainantu Gold Mine in the Eastern Highlands province of Papua New Guinea, as well as exploration and development of mineral deposits in the immediate vicinity of the mine. The Company declared commercial production from Kainantu in February 2018, is in a strong financial position, and is working to become a Tier 1 mid-tier producer through ongoing plant expansions. A maiden resource estimate on the Blue Lake copper-gold porphyry project was completed in August 2022. K92 is operated by a team of mining company professionals with extensive international mine-building and operational experience.
On Behalf of the Company,
John Lewins, Chief Executive Officer and Director
For further information, please contact David Medilek, P.Eng., CFA, President and Chief Operating Officer at +1-604-416-4445
CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING INFORMATION: This news release includes certain 'forward-looking statements' under applicable Canadian securities legislation. Such forward-looking statements include, without limitation: (i) the results of the Kainantu Mine Definitive Feasibility Study, including the Stage 3 Expansion, a new standalone 1.2 mtpa process plant and supporting infrastructure; (ii) statements regarding the expansion of the mine and development of any of the deposits; (iii) the Kainantu Stage 4 Expansion, operating two standalone process plants, larger surface infrastructure and mining throughputs; and (iv) the potential extended life of the Kainantu Mine.
All statements in this news release that address events or developments that we expect to occur in the future are forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, although not always, identified by words such as 'expect', 'plan', 'anticipate', 'project', 'target', 'potential', 'schedule', 'forecast', 'budget', 'estimate', 'intend' or 'believe' and similar expressions or their negative connotations, or that events or conditions 'will', 'would', 'may', 'could', 'should' or 'might' occur. All such forward-looking statements are based on the opinions and estimates of management as of the date such statements are made. Forward-looking statements are necessarily based on estimates and assumptions that are inherently subject to known and unknown risks, uncertainties and other factors, many of which are beyond our ability to control, that may cause our actual results, level of activity, performance or achievements to be materially different from those expressed or implied by such forward-looking information. Such factors include, without limitation, Public Health Crises, including the epidemic or pandemic viruses; changes in the price of gold, silver, copper and other metals in the world markets; fluctuations in the price and availability of infrastructure and energy and other commodities; fluctuations in foreign currency exchange rates; volatility in price of our common shares; inherent risks associated with the mining industry, including problems related to weather and climate in remote areas in which certain of the Company's operations are located; failure to achieve production, cost and other estimates; risks and uncertainties associated with exploration and development; uncertainties relating to estimates of mineral resources including uncertainty that mineral resources may never be converted into mineral reserves; the Company's ability to carry on current and future operations, including development and exploration activities at the Arakompa, Kora, Judd and other projects; the timing, extent, duration and economic viability of such operations, including any mineral resources or reserves identified thereby; the accuracy and reliability of estimates, projections, forecasts, studies and assessments; the Company's ability to meet or achieve estimates, projections and forecasts; the availability and cost of inputs; the availability and costs of achieving the Stage 3 Expansion or the Stage 4 Expansion; the ability of the Company to achieve the inputs the price and market for outputs, including gold, silver and copper; failures of information systems or information security threats; political, economic and other risks associated with the Company's foreign operations; geopolitical events and other uncertainties, such as the conflicts in Ukraine, Israel and Palestine; compliance with various laws and regulatory requirements to which the Company is subject to, including taxation; the ability to obtain timely financing on reasonable terms when required; the current and future social, economic and political conditions, including relationship with the communities in Papua New Guinea and other jurisdictions it operates; other assumptions and factors generally associated with the mining industry; and the risks, uncertainties and other factors referred to in the Company's Annual Information Form under the heading 'Risk Factors'.
Estimates of mineral resources are also forward-looking statements because they constitute projections, based on certain estimates and assumptions, regarding the amount of minerals that may be encountered in the future and/or the anticipated economics of production. The estimation of mineral resources and mineral reserves is inherently uncertain and involves subjective judgments about many relevant factors. Mineral resources that are not mineral reserves do not have demonstrated economic viability. The accuracy of any such estimates is a function of the quantity and quality of available data, and of the assumptions made and judgments used in engineering and geological interpretation, Forward-looking statements are not a guarantee of future performance, and actual results and future events could materially differ from those anticipated in such statements. Although we have attempted to identify important factors that could cause actual results to differ materially from those contained in the forward-looking statements, there may be other factors that cause actual results to differ materially from those that are anticipated, estimated, or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Aptose Reports Early Data Demonstrating Tuspetinib Improves Standard of Care Treatment Across Diverse Populations of Newly Diagnosed AML in Phase 1/2 TUSCANY Trial
Aptose Reports Early Data Demonstrating Tuspetinib Improves Standard of Care Treatment Across Diverse Populations of Newly Diagnosed AML in Phase 1/2 TUSCANY Trial

Yahoo

time23 minutes ago

  • Yahoo

Aptose Reports Early Data Demonstrating Tuspetinib Improves Standard of Care Treatment Across Diverse Populations of Newly Diagnosed AML in Phase 1/2 TUSCANY Trial

Addition of Tuspetinib (TUS) to Venetoclax (VEN) and Azacitidine (AZA) is being developed as safe and mutation agnostic frontline therapy for AML Addition of TUS to VEN+AZA improves response rates; 100% CR/CRh at 80 mg and 120 mg Addition of TUS to VEN+AZA improves MRD-negativity rates; 78% among responders 100% CR/CRh in FLT3 wildtype AML, representing 70% of AML population 100% CR/CRh and MRD-negativity rates in TP53, RAS and FLT3-ITD mutated AML Broad spectrum activity and excellent safety profile continue at 120 mg dose to date SAN DIEGO and TORONTO, Aug. 18, 2025 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. ('Aptose' or the 'Company') (OTC: APTOF, TSX: APS), a clinical-stage precision oncology company developing the tuspetinib (TUS)-based triple drug frontline therapy to treat patients with newly diagnosed AML, today provided a data update from the Phase 1/2 TUSCANY trial in newly diagnosed AML. The trial was initiated in December 2024, and the growing body of positive data includes the recently completed third cohort of 120 mg TUS in the TUS+VEN+AZA triplet therapy. Data to date from ten (10) patients across all three cohorts, 40 mg, 80 mg or 120 mg TUS dose in TUS+VEN+AZA, support the use of TUS with standard of care treatment across all AML populations, including those carrying mutations that are the most difficult to treat and those with mutated and unmutated (wildtype) FLT3 genes. The TUS+VEN+AZA triplet is being developed as a safe and well-tolerated mutation agnostic frontline therapy to treat large, mutationally diverse populations of newly diagnosed AML patients who are ineligible to receive induction chemotherapy. At the 120 mg TUS dose level in combination with VEN+AZA, as with the prior reported 40 mg and 80 mg TUS dose cohorts, no significant safety concerns or dose limiting toxicities (DLTs) have been observed in the TUSCANY trial, including no prolonged myelosuppression in Cycle 1 of subjects in remission, no reports of drug-related QTc prolongation or differentiation syndrome (DS), and no treatment-related deaths. Nine out of ten dosed patients remain on study across all dose cohorts and enrollment is being advanced to the 160 mg TUS dose level following the Cohort Safety Review Committee (CSRC) meeting. 'We already have data from three different TUS dose levels in the TUSCANY trial, and the data continue to strengthen at higher doses of TUS and over time. We are building a strong case for TUS+VEN+AZA as a triplet frontline therapy of choice to address a broad AML population, including subgroups with the most adverse of mutations,' said William G. Rice, Ph.D., Chairman, President and Chief Executive Officer of Aptose. Data highlights: Comparison of CR/CRh1 Response rates2-5: VEN+AZA2 TUS+VEN+AZA All subjects 65% 90% (9/10) NPM1-mutant 67% 100% (2/2) FLT3-ITD 61% 100% (2/2) TP53-mutant 52% 100% (2/2) Comparison of MRD-negativity6 rates among All Subjects and among CR/CRh Responders3: VEN+AZA2,3 TUS+VEN+AZA Among All Subjects 23.4% 70% (7/10) Among CR/CRh Responders 40.9% 78% (7/9) Comparison of MRD-negativity rates among more difficult-to-treat Patient Subpopulations defined as Lower Benefit (TP53-mutated) and Intermediate Benefit (FLT3-ITD or RAS-mutated) relative to VEN+AZA5: VEN+AZA3,5 TUS+VEN+AZA Intermediate Benefit 27.9% 100% (3/3) Lower Benefit 14.5% 100% (2/2) TUS+VEN+AZA - CR/CRh and MRD-negativity rates among Subjects with Adverse Mutations: TP53, FLT3-ITD, RAS mutations: Achieved CR/CRh and MRD-negativity 100% (5/5) 'As illustrated in the data highlights, the addition of TUS to VEN+AZA appears to boost response rates and MRD-negativity while maintaining favorable safety and tolerability,' said Rafael Bejar, M.D., Ph.D., Chief Medical Officer of Aptose, 'and the 100% CR/CRh and 100% MRD-negativity rates among the five biallelic TP53-mutant, FLT3-ITD, and RAS-mutant AML cases are exciting to see, as this can correlate with longer overall survival. We have observed a trend towards achieving CRs more quickly at the higher dose levels, so we are keen to see the activity as we advance into the 160 mg TUS dose cohort.' Key messages: Addition of TUS to VEN+AZA demonstrates excellent CR/CRh rates 100% CR/CRh among all subjects treated at 80 mg and 120 mg TUS dose levels Appear to be achieving CR earlier with 120 mg TUS than with 40 mg or 80 mg Addition of TUS to VEN+AZA demonstrates excellent MRD-negativity rates MRD-negativity in 7 of 9 (78%) already achieved in patients who responded to therapy Expect patient survival to be extended with continued long-term treatment Excellent safety and well tolerated with no dose-limiting toxicities (No DLT) at completed dose levels Broad-spectrum activity including patients with adverse TP53, RAS and FLT3-ITD mutations No loss of MRD-negativity observed to date, including in one patient with over 7 months of follow up MRD-negativity and remissions continue to mature over time on therapy No relapses reported to date and no treatment related deaths The only non-responder was a patient at the initial TUS dose level (40 mg) that did not achieve TUS exposures previously associated with response Additional data are included in the new Aptose corporate presentation here. TUSCANY: TUS+VEN+AZA Triplet Phase 1/2 Study The tuspetinib-based TUS+VEN+AZA triplet therapy is being advanced in the TUSCANY Phase 1/2 trial with the goal of creating an improved frontline therapy for newly diagnosed AML patients that is active across diverse AML populations, durable, and well tolerated. The TUSCANY triplet Phase 1/2 study, being conducted at 10 leading U.S. clinical sites by elite clinical investigators, is designed to test various doses and schedules of TUS in combination with standard dosing of AZA and VEN for patients with AML who are ineligible to receive induction chemotherapy. A convenient, once daily oral agent, TUS is being administered in 28-day cycles. Multiple U.S. sites are enrolling in the TUSCANY trial with anticipated enrollment of 18-24 patients by late 2025. Data will be released as it becomes available. More information on the TUSCANY Phase 1/2 study can be found on (here). About Aptose Aptose Biosciences is a clinical-stage biotechnology company committed to developing precision medicines addressing unmet medical needs in oncology, with an initial focus on hematology. The Company's lead clinical-stage, oral kinase inhibitor tuspetinib (TUS) has demonstrated activity as a monotherapy and in combination therapy in patients with relapsed or refractory acute myeloid leukemia (AML) and is being developed as a frontline triplet therapy in newly diagnosed AML. For more information, please visit Forward Looking Statements This press release may contain forward-looking statements within the meaning of Canadian and U.S. securities laws, including, but not limited to, statements relating to the therapeutic potential and safety profile of tuspetinib (including the triplet therapy) and its clinical development, the anticipated enrollment rate in the TUSCANY trial and the timing thereof, as well as statements relating to the Company's plans, objectives, expectations and intentions and other statements including words such as 'continue', 'expect', 'intend', 'will', 'should', 'would', 'may', and other similar expressions. Such statements reflect our current views with respect to future events and are subject to risks and uncertainties and are necessarily based upon a number of estimates and assumptions that, while considered reasonable by us are inherently subject to significant business, economic, competitive, political and social uncertainties and contingencies. Many factors could cause our actual results, performance or achievements to be materially different from any future results, performance or achievements described in this press release. Such factors could include, among others: our ability to obtain the capital required for research and operations and to continue as a going concern; the inherent risks in early stage drug development including demonstrating efficacy; development time/cost and the regulatory approval process; the progress of our clinical trials; our ability to find and enter into agreements with potential partners; our ability to attract and retain key personnel; changing market conditions; inability of new manufacturers to produce acceptable batches of GMP in sufficient quantities; unexpected manufacturing defects; and other risks detailed from time-to-time in our ongoing quarterly filings, annual information forms, annual reports and annual filings with Canadian securities regulators and the United States Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should the assumptions set out in the section entitled 'Risk Factors' in our filings with Canadian securities regulators and the United States Securities and Exchange Commission underlying those forward-looking statements prove incorrect, actual results may vary materially from those described herein. These forward-looking statements are made as of the date of this press release and we do not intend, and do not assume any obligation, to update these forward-looking statements, except as required by law. We cannot assure you that such statements will prove to be accurate as actual results and future events could differ materially from those anticipated in such statements. Investors are cautioned that forward-looking statements are not guarantees of future performance and accordingly investors are cautioned not to put undue reliance on forward-looking statements due to the inherent uncertainty therein. For further information, please contact: Aptose Biosciences PietropaoloCorporate Communications & Investor Relations201-923-2049spietropaolo@ 1 Complete Response / Complete Response with Partial Hematological Recovery2 DiNardo et al. New England Journal of Medicine, August 2020; Volume 383(7):617-629.3 Pratz et al. Journal of Clinical Oncology, December 2021; Volume 40 (8):855-865.4 Othman et. al. Blood Neoplasia; September 2024; Volume 1 (3):1-11.5 Döhner et. al. Blood. 2024 November 21;144(21):2211-2222.6 MRD-negative indicates that the amount of Measurable Residual Disease, as assessed by central flow cytometry, is such that the proportion of leukemic cells in a bone marrow sample falls below <0.1%Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

The Apache Software Foundation Announces Apache Ozone 2.0.0
The Apache Software Foundation Announces Apache Ozone 2.0.0

Yahoo

time36 minutes ago

  • Yahoo

The Apache Software Foundation Announces Apache Ozone 2.0.0

First object store to support operational databases, now with major usability and compatibility enhancements Wilmington, DE, Aug. 19, 2025 (GLOBE NEWSWIRE) -- The Apache Software Foundation (ASF), the global home of open source software the world relies on, today announced Apache Ozone 2.0.0, a major milestone for the cloud-native distributed object store built for big data, analytics, and AI workloads. "Apache Ozone 2.0.0 represents years of community collaboration and production lessons from large-scale deployments,' said Sammi Chen, Apache Ozone PMC Chair and Principal Engineer at Cloudera. 'We're seeing growing adoption of Ozone in production, and this release brings the stability, performance, and ecosystem integration users have asked for." Ozone 2.0.0 responds to growing demand from organizations building AI and analytics platforms that require scalable, fault-tolerant, and cost-efficient storage—without giving up on performance or operational ease. Key Highlights of Apache Ozone 2.0.0: Operational Database Support: Apache Ozone is the first object store to support Apache HBase, enabling low-latency read/write workloads alongside traditional object storage. Atomic Key Operations: Support for atomic key overwrite and key replacement improves consistency for applications running concurrently. Modernized Recon UI: The Ozone Recon monitoring interface has been redesigned for clarity, with better metrics and navigation to support administrators. Expanded Platform Support: Now compatible with JDK 17 and JDK 21, and builds natively on ARM64, enabling broader deployment options. Improved Snapshots: Snapshot operations are more robust and efficient, particularly in large-scale environments with frequent replication or churn. Day-2 Operations: SCM decommissioning is now supported, making it easier to safely remove or rotate hardware as part of lifecycle management. With version 2.0.0, Apache Ozone continues its evolution from an object store for Apache Hadoop to a modern, cloud-native storage platform designed for AI, data lakehouses, and hybrid cloud use cases. For more information on Apache Ozone 2.0.0 and to get started, visit Additional Resources: Download: Documentation: Blog: GitHub: Follow on X/Twitter: @ApacheOzone About The Apache Software Foundation (ASF)The Apache Software Foundation (ASF) is the global home for open source software, powering some of the world's most ubiquitous software projects including Apache Airflow, Apache Camel, Apache Cassandra, Apache Groovy, Apache HTTP Server, and Apache Kafka. Established in 1999, the ASF is at the forefront of open source innovation, setting industry standards to advance software for the public good. Learn more at ASF's annual Community Over Code event is where open source technologists convene to share best practices and use cases, forge critical relationships, and learn about advancements in their field. © The Apache Software Foundation. 'Apache' is a registered trademark or trademark of the Apache Software Foundation in the United States and/or other countries. All other brands and trademarks are the property of their respective Brian Proffitt press@ Vice President, Marketing & Publicity The Apache Software FoundationError in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Is Wheaton Precious Metals Stock a Buy?
Is Wheaton Precious Metals Stock a Buy?

Yahoo

timean hour ago

  • Yahoo

Is Wheaton Precious Metals Stock a Buy?

Written by Aditya Raghunath at The Motley Fool Canada With gold prices hovering near all-time highs, the share prices of mining companies such as Wheaton Precious Metals (TSX:WPM) have delivered solid returns in 2025. Valued at a market cap of almost $60 billion, Wheaton Precious Metals stock is up close to 60% in the past year. Moreover, the TSX stock has returned over 600% since August 2015. As past returns should be taken with a pinch of salt, let's see if you should invest in this gold mining stock at the current valuation. The bull case of investing in WPM stock Wheaton Precious Metals is a Vancouver-based precious metals streaming company that generates revenue through streaming agreements rather than operating mines directly. It purchases metal streams from mining operators by making upfront payments and ongoing delivery payments, then sells gold, silver, palladium, platinum, and cobalt across global markets, including North America, Europe, Africa, and South America. Wheaton targets 40% production growth to 870,000 gold equivalent ounces by 2029, driven by existing operations and new development projects. The company actively evaluates streaming and royalty opportunities, maintaining a robust pipeline of double-digit opportunities, including development-stage projects, secondary royalty sales, balance sheet repair situations, and asset rationalizations by senior mining companies. Wheaton Precious Metals reported exceptional second-quarter results, achieving record revenue, adjusted net earnings, and operating cash flow. It generated record quarterly revenue of $503 million, a 68% increase from the prior year, driven by strong commodity prices and 28% higher sales volumes. Net earnings surged 139% to $292 million, while operating cash flow increased 77% to $450 million. These gains outpaced commodity price increases, highlighting the leverage inherent in Wheaton's streaming model, where 85% of revenue comes from fixed per-ounce payments. Production reached 159,000 gold equivalent ounces, up 9% year over year, led by strong performances at Salobo and Antamina. Key growth catalysts materialized as Blackwater achieved commercial production and Goose delivered its first gold pour. The company remains well-positioned to achieve 2025 guidance of 600,000-670,000 gold equivalent ounces. Management revealed an active pipeline of 12-15 opportunities totalling billions in potential transactions, with two-thirds representing development-stage projects. The competitive environment hasn't restricted deal terms but has intensified competition. Wheaton maintains its disciplined approach, focusing only on accretive opportunities that enhance shareholder value. With over $1 billion in cash and a $2 billion undrawn credit facility, Wheaton possesses industry-leading liquidity to fund commitments and pursue additional acquisitions. The company's 40% production growth target by 2029 provides flexibility to be selective while capitalizing on the strengthening precious metals market. Silver's recent outperformance particularly benefits Wheaton, given its substantial silver exposure that differentiates it from streaming peers and positions WPM stock to capitalize on continued precious metals momentum. What is the target price for the TSX stock? Analysts tracking Wheaton Precious Metals stock forecast adjusted earnings to grow from $1.4 per share in 2024 to $2.58 per share in 2029. A widening earnings base should help it increase annual dividends per share from $0.62 in 2024 to $1.27 in 2029. Today, WPM stock trades at a forward price-to-earnings multiple of 37 times, which is higher than its 10-year average of 34 times. As gold prices stabilize, WPM stock might trade at a lower multiple going forward. So, if it's valued at 30 times earnings, WPM stock should trade around $80 in early 2029, below the current price of $94. The post Is Wheaton Precious Metals Stock a Buy? appeared first on The Motley Fool Canada. Should you invest $1,000 in Shopify right now? Before you buy stock in Shopify, consider this: The Motley Fool Stock Advisor Canada analyst team identified what they believe are the 15 best stocks for investors to buy now… and Shopify wasn't one of them. The 15 stocks that made the cut could potentially produce monster returns in the coming years. Consider MercadoLibre, which we first recommended on January 8, 2014 … if you invested $1,000 in the 'eBay of Latin America' at the time of our recommendation, you'd have $24,427.64!* Now, it's worth noting Stock Advisor Canada's total average return is 94%* – a market-crushing outperformance compared to 61%* for the S&P/TSX Composite Index. Don't miss out on our top 15 list, available when you join Stock Advisor Canada. See the 15 Stocks * Returns as of July 15th, 2025 More reading 10 Stocks Every Canadian Should Own in 2025 3 Canadian Companies Powering the AI Revolution Fool contributor Aditya Raghunath has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. 2025

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store